Abstract 375P
Background
The NAME study aims at investigating whether the treatment with Navelbine, according to the metronomic principle, is superior to conventional treatment in terms of efficacy and safety. The study has the EUDRACT no: 2016-002165-63. In addition to better efficacy, preliminary studies show treatment with frequent small dosages, not only have an effect on the tumour cells, but also, an effect on the angiogenesis and the immune cells.
Methods
The NAME trial is an open randomized multicentre phase II study. We included 163 patients with HER2 normal metastatic breast cancer in Denmark from 2017-2022. Both patients with Estrogenic receptor (ER) positive and ER negative tumours were included in the study. The randomisation is between the standard Arm A, where the patients are treated with Vinorelbine (Navelbine Oralâ): 60 mg/m2 day 1 and day 8, every three weeks for the first cycle. Hereafter 80 mg/m2 in the following cycles. In the metronomic experimental Arm B, the patients receive Vinorelbine (Navelbine Oralâ): daily doses of Navelbine. The start dose is 30 mg per day. Reduction is possible.
Results
The patients were well balanced between the two arms. Median age were 68-69 years. Primarily performance status 0-1. The adverse events found in the study shows the two regimes were both well tolerated with mostly low-grade adverse events. We found a median progression free survival (PFS) in arm A of 3.9 months (95% CI 3.4-4.5) and a median PFS in arm B of 2.3 months (95% CI 1.5-3.0). The difference was non-significant (P=0.236). The median overall survival (OS) was 16.63 months (95% CI 14.66-18.61) in arm A and 15.13 months (95% CI 12.11-18.16) in arm B. Also, non-significant (P=0.355).
Conclusions
The study was conducted in order investigate metronomic chemotherapy using a randomized trial design. There was no significant difference between the two arms regarding effect. No new signals regarding safety were observed. While metronomic chemotherapy may offer certain advantages, our findings could not demonstrate any benefit, when using Navelbine in advanced breast cancer patients in this particular investigator initiated, multicentre, Danish randomised controlled trial, the NAME trial.
Clinical trial identification
EudraCT 2016-002165-63 The NAME trial.
Editorial acknowledgement
Legal entity responsible for the study
Anne Sofie Brems-Eskildsen.
Funding
Pierre Fabre, Overture's Torg 1, Plan 2 SE-19147 Sollentuna Sweden.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
414P - The complex relationship between circulating tumor cells (CTCs) and brain metastases (BMs) in metastatic breast cancer (mBC): A retrospective pooled analysis
Presenter: Brenno Pastò
Session: Poster session 15
415P - Comprehensive liquid biopsy characterization of patients with metastatic inflammatory breast cancer
Presenter: Eleonora Nicolo
Session: Poster session 15
417P - EV derived miR-21 as a promising biomarker for early diagnosis and tumor activity in discrete BC subtypes: The Exobreast project
Presenter: Claudia Omarini
Session: Poster session 15
418P - Concordance of PI3K-AKT pathway alterations between tumor and ctDNA in metastatic breast cancer
Presenter: Charlton Tsai
Session: Poster session 15
419P - Prevalence of gene rearrangement on ctDNA NGS and its targetability in patients with advanced breast cancer
Presenter: Ankur Bahl
Session: Poster session 15
420P - An exosome-based ESR1 monitoring RT-qPCR kit that rapidly and accurately detects acquired resistance variants at ≤ 0.1% frequency in liquid biopsy samples
Presenter: Sarah Statt
Session: Poster session 15
421P - Impact of novel agents in patients with stage IV denovo HR+ve/Her2-ve breast cancer: Results from a real-world dataset
Presenter: Shaheenah Dawood
Session: Poster session 15
422P - Disparities in treatment delays among metastatic breast cancer patients: Insights from nationwide electronic health records, 2011-2022
Presenter: Asal Pilehvari
Session: Poster session 15
423P - Marginalization and factors associated with early mortality among patients diagnosed with de novo metastatic breast cancer in Ontario, Canada
Presenter: Priya Thomas
Session: Poster session 15